Literature DB >> 15053177

Acute tumor lysis syndrome caused by palliative radiotherapy in patients with diffuse large B-cell lymphoma.

Hideya Yamazaki1, Masato Hanada, Masashi Horiki, Jun Kuyama, Tadayuki Sato, Miki Nishikubo, Takeshi Ishida, Takehiro Inoue.   

Abstract

Acute tumor lysis syndrome (TLS) is a condition that results from the rapid destruction of tumor cells accompanied with a massive release of cellular breakdown products. Acute renal failure resulting from TLS has been reported in cases of hematologic malignancies, spontaneous or treatment induced, the latter especially by chemotherapy. We present the case of a patient with diffuse large B-cell lymphoma who developed radiotherapy-induced TLS and subsequently acute renal failure. He presented with a large mediastinal tumor compressing the airway, thus causing dyspnea. After 6 Gy/3 fractions/3 days of palliative radiotherapy for the tumor, a decrease in urine volume was noted as well as rapid tumor shrinking. Because this patient died despite previous prophylaxic anti-uric acid treatment and hemodialysis, his case illustrates the need to anticipate the development of acute renal failure, even though there may be no remarkable serum uric acid elevation after the initiation of radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15053177

Source DB:  PubMed          Journal:  Radiat Med        ISSN: 0288-2043


  2 in total

1.  Cytokine release syndrome and tumor lysis syndrome in a multiple myeloma patient treated with palliative radiotherapy: A case report and review of the literature.

Authors:  Axel Cailleteau; Cyrille Touzeau; Bastien Jamet; Valentine Guimas; Emmanuel Jouglar; Stéphane Supiot
Journal:  Clin Transl Radiat Oncol       Date:  2021-11-12

2.  Tumor lysis syndrome during radiotherapy for prostate cancer with bone and bone marrow metastases without visceral metastasis.

Authors:  Muhammet Ali Kaplan; Mehmet Kucukoner; Gulistan Alpagat; Abdurrahman Isikdogan
Journal:  Ann Saudi Med       Date:  2012 May-Jun       Impact factor: 1.526

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.